Phase 2
N=22
Hydroxyproline Influence on Oxalate Metabolism
Hyperoxaluria
Bottom Line
View on ClinicalTrials.gov: NCT02038543 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcome: Primary: Mean Percent Conversion of Hydroxyproline (Hyp) to Urinary Oxalate (UOx) — 12.8; 32.9; 14.8 percent converted
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Hydroxyproline and Leucine (Drug)
- Age
- Pediatric, Adult, Older Adult · 15+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Sep 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Percent Conversion of Hydroxyproline (Hyp) to Urinary Oxalate (UOx) |
12.8; 32.9; 14.8 | — |
| SECONDARY Mean Percent Conversion of Hydroxyproline (Hyp) to Urinary Glycolate (UGIc) |
16.3; 1.4; 2.5 | — |
Summary
Primary hyperoxaluria is an inborn error of metabolism that results in marked overproduction of oxalate by the liver. The excess oxalate causes kidney failure and can cause severe systemic disease due to oxalate deposition in multiple body tissues.
Metabolic pathways that lead to oxalate are poorly understood, but recent evidence suggests that hydroxyproline may play a role. Sources of hydroxyproline include the diet and bone turnover. If hydroxyproline can be confirmed as a significant factor in primary hyperoxaluria, diet modification might be of value in reducing the severity of disease.
This protocol, in which hydroxyproline labelled with a cold isotope is infused intravenously in patients with primary hyperoxaluria, will allow the researchers to measure the amount of oxalate produced from hydroxyproline. The contribution of hydroxyproline metabolism to the amount of oxalate excreted in urine in will be able to be determined for patients with each of the known types of primary hyperoxaluria.
Eligibility Criteria
Inclusion criteria
- Confirmed diagnosis of primary hyperoxaluria (PH)
- Estimated Glomerular Filtration Rate (eGFR) (by serum creatinine) > 50ml/min/1.73m^2 - Patients with a diagnosis of PH I, PH II, PH III, or Non I/Non II/Non III PH (PH types will be confirmed by DNA)
Exclusion criteria
- eGFR < 50 ml/min/1.73m^2
- History of liver or kidney transplant
- Primary hyperoxaluria patients who have responded to pyridoxine therapy with reduction of urine oxalate excretion to < 0.45 mmol/1.73m^2/day
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT02038543). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.